Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention
Gianluca Campo,
Rita Pavasini,
Giampaolo Morciano,
Michael A. Lincoff,
Michael C. Gibson,
Masafumi Kitakaze,
Jacob Lonborg,
Amrita Ahluwalia,
Hideki Ishii,
Michael Frenneaux,
Michel Ovize,
Marcello Galvani,
Dan Atar,
Borja Ibanez,
Giampaolo Cerisano,
Simone Biscaglia,
Brandon J. Neil,
Masanori Asakura,
Thomas Engstrom,
Daniel A. Jones,
Dana Dawson,
Roberto Ferrari,
Paolo Pinton,
Filippo Ottani
Affiliations
Gianluca Campo
Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona, FE, Italy
Rita Pavasini
Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona, FE, Italy
Giampaolo Morciano
Department of Morphology, Surgery and Experimental Medicine. Section of Pathology, Oncology and Experimental Biology, University of Ferrara, Ferrara, Italy
Michael A. Lincoff
Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH, USA
Michael C. Gibson
PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Masafumi Kitakaze
Cardiovascular Division of Medicine, National Cardiovascular Centre, Suita, Osaka, Japan
Jacob Lonborg
Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
Amrita Ahluwalia
Centre of Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, William Harvey Research Institute, Barts & The London Medical School, Queen Mary University, London, UK
Hideki Ishii
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Michael Frenneaux
Norwich Medical School, University of East Anglia, Norwich, UK
Michel Ovize
Clinical Investigation Center of Lyon, Lyon, France
Marcello Galvani
Unità Operativa di Cardiologia, Ospedale GB Morgagni, Forlì, Italy
Dan Atar
Department of Cardiology B, Oslo University Hospital Ullevall, and Faculty of Medicine, University of Oslo, Oslo, Norway
Borja Ibanez
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain and Instituto de Investigación-Fundación Jiménez Díaz Hospital, Madrid, Spain
Giampaolo Cerisano
Division of Cardiology, University of Florence, Careggi Hospital, Florence, Italy
Simone Biscaglia
Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona, FE, Italy
Brandon J. Neil
PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Masanori Asakura
Cardiovascular Division of Medicine, National Cardiovascular Centre, Suita, Osaka, Japan
Thomas Engstrom
Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
Daniel A. Jones
Centre of Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, William Harvey Research Institute, Barts & The London Medical School, Queen Mary University, London, UK
Dana Dawson
School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK
Roberto Ferrari
Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona, FE, Italy
Paolo Pinton
Department of Morphology, Surgery and Experimental Medicine. Section of Pathology, Oncology and Experimental Biology, University of Ferrara, Ferrara, Italy
Filippo Ottani
Unità Operativa di Cardiologia, Ospedale GB Morgagni, Forlì, Italy
Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high [1]. A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion [2]. Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results [3–16]. Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome [17]. Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil [3–5,9–11], excluding a trial on metoprolol [12] and comparing trial with follow-up length <12 months versus those with longer follow-up [3–16]. This article describes data related article titled “Clinical Benefit of Drugs Targeting Mitochondrial Function as an Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction: a Meta-Analysis of Randomized Clinical Trials” [17].
